Enliven Therapeutics, Inc. (NasdaqGS: ELVN)
Health Care · Pharmaceuticals · US
$40.63
-1.76% today · +100.0% 1Y
Enliven Therapeutics, Inc. (NasdaqGS: ELVN) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.98B and employs 67 people.
Over the last twelve months the share price has gained 100.0%, trading between 14.79 and 62.32.
Tweenvest scores Enliven Therapeutics, Inc. across four factors: quality 41/100, value 91/100. Its strongest factor is value.
ELVN price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.98B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.67
- Dividend yield
- —
- Beta (5Y)
- 0.34
- 52-week high
- $62.32
- 52-week low
- $14.79
- Avg volume (3M)
- —
- Shares outstanding
- 73.27M
- Employees
- 67
- Next earnings
- —
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
- ISIN
- US29337E1029
- Founded
- 2019
- Listed since
- Mar 12, 2020
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd.SEHK: 6887 | $3.09B | HK$42.12 | +6.36% |
| Guangdong Zhongsheng Pharmaceutical Co., Ltd.SZSE: 002317 | $3.04B | CN¥24.03 | +2.91% |
| Jilin Aodong Pharmaceutical Group Co., Ltd.SZSE: 000623 | $3.04B | CN¥17.41 | -0.40% |
| Chengdu Kanghong Pharmaceutical Group Co., LtdSZSE: 002773 | $2.99B | CN¥21.80 | +6.76% |
| Virbac SAENXTPA: VIRP | $2.96B | €315.50 | -0.79% |
| Neuland Laboratories LimitedBSE: 524558 | $2.86B | Rs21,496.30 | -1.86% |
| MBX Biosciences, Inc.NasdaqGS: MBX | $2.82B | $53.25 | -8.99% |
| Rubicon Research LimitedNSEI: RUBICON | $2.80B | Rs1,630.90 | -2.71% |
Figures last refreshed Oct 4, 2026.